Lung cancer IHC portfolio

Lung assays

Deliver diagnostic confidence with the lung IHC portfolio

 

The statistics associated with lung cancer clearly demonstrate the aggressive nature of this deadly disease. Roche Diagnostics offers a robust menu of lung cancer diagnostic tools.

 

VENTANA prediluted, optimized reagents

 

Our antibodies are ready-to-use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. VENTANA prediluted, optimized reagents consistently demonstrate superior performance when compared with concentrated antibodies that require manual dilution and in-house validation.

 

Proven portfolio of lung cancer assays

 

Our proven portfolio of lung cancer assays can assist in the stratification of disease, including non-small cell lung carcinoma (NSCLC), neuroendocrine carcinoma and their various subtypes.

p40
p40 (BC28) Mouse Monoclonal Primary Antibody1

 

  • Found to be as or more sensitive than p632,3,4
  • Studies indicate p40 has higher specificity in squamous cell carcinoma than p632,3,4
  • May offer a suitable replacement for p63 in various tumor types5,6
  • Can be used in a stratification panel with other key markers7,8
immunohistochemical staining with Basal Cell Cocktail 34ßE12 + p63
TTF-1 (SP141) Rabbit Monoclonal Primary Antibody

 

  • Aids in investigation of metastatic carcinomas of unknown origin9
  • Equal or better lung carcinoid detection than other on-market clones10
  • Commonly used in lung stratification panels with other key markers7,8
immunohistochemical staining with Basal Cell Cocktail 34ßE12 + p63
Cytokeratin 5/6 (D5/16B4) Mouse Monoclonal Primary Antibody

 

  • Aids in the identification of squamous cell carcinoma11
  • Aids in the differentiation of malignant mesothelioma from lung adenocarcinoma12
  • Commonly used in a stratification panel with other markers7,8
immunohistochemical staining with Basal Cell Cocktail 34ßE12 + p63
Napsin A (MRQ-60) Mouse Monoclonal Primary Antibody

 

  • Useful in the identification of primary and metastatic carcinomas of the lung13
  • Highly specific for lung adenocarcinoma7
  • Commonly used in a lung stratification panel with other key markers7,8
Catalogue de produits Ventana - Réactifs et accessoires

Catalogue de réactifs

Réactifs, accessoires, notices d’utilisation et Safety Data Sheets pour l’IHC et l’ISH

eLabDoc

Catalogue de réactifs

  1. Assessment Run 48 p40 (ΔNp63) NordiQC. http://www.nordiqc.org/downloads/assessments/83_10.pdf Updated 2016, accessed 21 MAR 2017
  2. Bishop, Justin A, Julie Teruya-Feldstein, William H Westra, Giuseppe Pelosi, William D Travis and Natasha Rekhtman. p40 (∆Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology. 2012 Mar;25(3):405-15.
  3. Chen, Xiangbai, Yunhau Bao, Rebecca Wong, Katerina Politi, Lizhuo Jiao, Scott Gettinger, Robert Homer, David Chieng, Guoping Cai. [351] The Role of p40 Immunostain in the Cytological Differential Diagnosis of Squamous Cell Carcinoma and Adenocarcinoma of the Lung. USCAP Abstract. 2013
  4. Vogt, Adam P, Cynthia Cohen, Momin T Siddiqui. [436] p40 (ΔNp63): A Highly Sensitive and Specific Immunohistochemical (IHC) Marker for Diagnosing Pulmonary Squamous Cell Carcinomas (SQCC) in Fine Needle Aspirates. USCAP Abstract. 2013.
  5. Tacha, David PhD; Ryan Bremer, PhD; Thomas Haas, DO; Weiman Qi, PhD, MD. An Immunohistochemical Analysis of a Newly Developed, Mouse Monoclonal p40 (BC28) Antibody in Lung, Bladder, Skin, Breast, Prostate and Head and Neck Cancers. Arch Pathol Lab Med—Vol 138, October 2014.
  6. Sailer et al. Comparison of p40 (DNp63) and p63 expression in prostate tissues – which one is the superior diagnostic marker for basal cells? Histopathology. 2013. 63: 50–56.
  7. Wei Zhao, Hui Wang, Yan Peng, Bo Tian, Lei Peng, Da-Chuan Zhang. ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol. 2014; 7(7): 4247–4253.
  8. Kai Zhang, Hongbin Deng, and Philip T. Cagle (2014) Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update. Archives of Pathology & Laboratory Medicine: December 2014, Vol. 138, No. 12, pp. 1611-1628.
  9. Daniel Misch, Torsten Blum, Christian Boch, Timo Weiss, Catharina Crolow, Sergej Griff, Thomas Mairinger, Torsten T Bauer and Jens Kollmeier. Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer. Diagnostic Pathology (2015) 10:21
  10. Lung cancer diagnostic solutions product brochure (7009A-5)
  11. A. Kargi, D. Gurel, B. Tuna, The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):415-20.
  12. N.G. Ordòñez. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998 Oct;22(10):1215-21.
  13. Ye J, Findeis-Hosey JJ, Yang Q, McMahon LA, Yao JL, Li F, Xu H. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):313-7.